Dermata Therapeutics, Inc. Common Stock DRMA
Analyst Ratings
- Consensus
- Buy — 1 Buy · 0 Hold · 0 Sell (1 analysts)
- Avg. Price Target
- $10.00 (+584.9% upside)
Key Stats
- Today's Range
- $1.40 – $1.55
- 50-Day Range
- $0.95 – $1.62
- 52-Week Range
- $0.95 – $8.00
- Volume
- 422K shs
- Average Volume
- 1.44 million shs
- Market Cap
- $5.87 million
- P/E Ratio
- —
- Dividend Yield
- —
Short Interest
- Short Interest
- 0.40%
- Days to Cover
- 1.00
About Dermata Therapeutics, Inc. Common Stock
Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
Related Stocks
Compare head-to-head: DRMA vs LLY·DRMA vs JNJ·DRMA vs ABBV·DRMA vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.